Delivery Order SPE2DB24D2216-SPE2DB25FGPKE
- Not listed
- AmerisourceBergen Drug Corp was awarded a Delivery Order contract by the Defense Logistics Agency (DLA) on August 5, 2025, for the supply of RINVOQ ER 15 MG tablets in quantities of 30 units. This firm fixed price delivery order, valued at $11,576.19, represents a non-competitive award under DLA's pharmaceutical supply chain supporting federal medical procurement needs. The contract is scheduled for completion by August 6, 2025, with performance originating from AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $26,154.99 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of RINVOQ ER 30 mg tablets (quantity: 30-unit bottles). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $32,318.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $274,266.46 by the Defense Logistics Agency's Medical Supply Chain to supply RINVOQ ER 45 mg tablets in a quantity of 28 units. The contract was awarded on July 22, 2025, with an ultimate completion date of July 23, 2025, utilizing firm fixed-price pricing with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for RINVOQ ER 15 mg tablets (30-unit bottles) under a firm fixed-price contract valued at $10,362.56. This is a non-set-aside competitive award with an ultimate completion date of July 30, 2025. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a $80,832.18 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract involves no set-aside...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $14,917.09 for RINVOQ ER 30 MG Tablet (UU 30s) by the Defense Logistics Agency Medical Supply Chain. The contract, awarded on July 22, 2025, with an ultimate completion date of July 23, 2025, utilizes firm fixed pricing and is classified as a non-set-aside competitive award. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $42,368.91 to AmerisourceBergen Drug Corp for RINVOQ ER 30 MG tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $30,927.58 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This is a firm fixed-price, non-set-aside contract executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion global pharmaceutical support vehicle running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $42,773.33 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is listed...
- SPE2DB24D2216Indefinite Delivery Contract
- SPE2DB24D2216-SPE2DB25FGPKEDelivery Order
AmerisourceBergen Drug Corp was awarded a delivery order valued at $40,276.41 by the Defense Logistics Agency on August 4, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The order will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 5, 2025. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for federal military and healthcare programs. The Defense Logistics Agency's Medical Supply Chain utilizes AmerisourceBergen Drug Corp as a critical pharmaceutical distributor to support military healthcare systems and other federal medical procurement needs. RINVOQ ER, a rheumatoid arthritis treatment, represents the type of specialty medication included within the contractor's extensive portfolio of brand-name and generic pharmaceutical products. AmerisourceBergen Drug Corp's consistent receipt of competitively awarded delivery orders across multiple therapeutic domains demonstrates its capability to meet federal procurement requirements and serve customers including the Defense Health Agency and U.S. Coast Guard through flexible contract vehicles that support worldwide military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $40.3k | 8/4/25 |